Back

Transcriptional regulators FOXD1 and RBFOX2 contribute to metastatic capacity in BAP1mut uveal melanoma

Brosens, E.; Nguyen, J.; Konemann, N.; van den Bosch, T.; Verdijk, R.; Kilic, E.; van den Bosch, Q.

2025-04-18 cancer biology
10.1101/2025.04.14.648661 bioRxiv
Show abstract

Uveal melanoma is the most prevalent primary intraocular cancer, with a significant metastatic risk. This risk is dependent on the genetic drivers. Secondary mutations in EIF1AX, SF3B1 and BAP1 correlate with clinical outcomes and are recognized for their distinct transcriptomic and epigenetic profiles. Previously, we identified 480 genes involved in the development of ocular melanocytes. Top ranking genes RBFOX2 and FOXD1 were significantly associated with BAP1 UM and were independently correlated to poor progression. However, it is uncertain whether either RBFOX2 or FOXD1 have biological contribution to disease progression or are solely indicative. This study investigates if and how these high-risk associated transcription regulators FOXD1 and RBFOX2 could influence tumor progression through knock-out and overexpression models. Our results indicate that loss of RBFOX2 affects cell morphology, attachment and proliferation, particularly in BAP1neg cells. Additionally, both RBFOX2 and FOXD1 contribute to tumor growth and dissemination in zebrafish xenografts. Loss of either RBFOX2 or FOXD1 reduced tumor volume and cell dissemination, with the greatest effects seen in BAP1neg cells. Overexpression models demonstrated different morphological and invasive behavior depending on the genetic background, suggesting complex roles in a context dependent fashion. Overexpression of RBFOX2 did not alter BAP1pos cells yet made BAP1neg cells more aggressive in vitro and in vivo. This study underscores the influence of RBFOX2 and FOXD1 as important factors for UM progression.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.1%
19.0%
2
Pigment Cell & Melanoma Research
11 papers in training set
Top 0.1%
10.3%
3
Scientific Reports
3102 papers in training set
Top 9%
8.6%
4
British Journal of Cancer
42 papers in training set
Top 0.1%
8.6%
5
PLOS ONE
4510 papers in training set
Top 25%
6.9%
50% of probability mass above
6
Experimental Dermatology
10 papers in training set
Top 0.1%
3.7%
7
International Journal of Cancer
42 papers in training set
Top 0.3%
2.9%
8
Frontiers in Oncology
95 papers in training set
Top 2%
2.4%
9
Oncogene
76 papers in training set
Top 0.8%
2.1%
10
BMC Cancer
52 papers in training set
Top 1%
1.7%
11
Molecular Oncology
50 papers in training set
Top 0.4%
1.5%
12
PeerJ
261 papers in training set
Top 10%
1.2%
13
Cell Communication and Signaling
35 papers in training set
Top 0.6%
1.2%
14
The Journal of Pathology
22 papers in training set
Top 0.3%
1.0%
15
Frontiers in Genetics
197 papers in training set
Top 8%
0.9%
16
Cells
232 papers in training set
Top 6%
0.8%
17
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 9%
0.8%
18
Cancer Medicine
24 papers in training set
Top 1%
0.8%
19
iScience
1063 papers in training set
Top 31%
0.8%
20
Acta Neuropathologica Communications
81 papers in training set
Top 1%
0.7%
21
PLOS Genetics
756 papers in training set
Top 15%
0.7%
22
Nature Communications
4913 papers in training set
Top 65%
0.7%
23
eLife
5422 papers in training set
Top 61%
0.7%
24
Biomolecules
95 papers in training set
Top 3%
0.5%
25
Neoplasia
22 papers in training set
Top 0.9%
0.5%
26
Cell Death & Disease
126 papers in training set
Top 3%
0.5%
27
Cancer Research
116 papers in training set
Top 4%
0.5%
28
European Journal of Cancer
10 papers in training set
Top 0.7%
0.5%
29
Frontiers in Ecology and Evolution
60 papers in training set
Top 5%
0.5%
30
Evolutionary Applications
91 papers in training set
Top 2%
0.5%